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Introduction: Docetaxel is a chemotherapeutic agent used alone or in combination for the management of many
neoplastic conditions. Numerous side effects are well described as a consequence. Palmar-plantar
erythrodysesthesia, although a relatively common side effect of some types of chemotherapy, occurs infrequently
with docetaxel and is often attributed to other drug agents.
Case Presentation: We report the case of a 66-year-old Caucasian woman who received adjuvant docetaxel
monotherapy for invasive breast cancer. She developed palmar-plantar erythrodysesthesia following her first cycle
of treatment, which necessitated a change in management.
Conclusion: Palmar-plantar erythrodysesthesia is a relatively common side effect of cytotoxic chemotherapy,
particularly with drugs such as 5-fluorouracil, capecitabine and liposomal doxorubicin. Docetaxel is commonly used
both alone and in combination with a number of these agents for the management of various malignant
conditions. We would like to highlight the occurrence of palmar-plantar erythrodysesthesia as a result of docetaxel
monotherapy so that it can be considered as a potential cause in patients receiving combination treatment with
chemotherapeutic agents better known to cause this toxicity.
Introduction
Docetaxel is a frequently used chemotherapeutic agent
belonging to the taxane family. It was first discovered in
1986 and is a semi-synthetic compound derived from
the needles of the European yew (Taxus baccata)[ 1 ] .I t
exerts its anti-cancer effect by promoting microtubule
stabilization, leading to mitotic arrest and subsequent
cell death [2]. It is used alone or in combination with
other chemotherapeutic agents for the management of
various malignant conditions including breast, prostate,
gastric, head and neck and non-small cell lung cancer
[3]. Docetaxel is known to cause a number of side
effects including hypersensitivity reactions, alopecia,
nausea, vomiting, peripheral neuropathy, myelosuppres-
sion, diarrhea, mucositis, fluid retention, myalgia,
arthralgia, nail changes and cutaneous reactions [3].
A number of skin reactions have been described in asso-
ciation with docetaxel, of which limb and/or palmar-
plantar erythematous (PPE) reactions and fixed plaque
erythrodysesthesia are amongst the more common [4].
Case presentation
A 66-year-old Caucasian woman was referred to us for
further investigation after noticing a lump in her right
breast. Initial investigations were performed and she
proceeded to have a right mastectomy and axillary
node clearance. Histology revealed an 11.5 cm invasive
lobular carcinoma with 8 out of 10 axillary lymph
nodes containing metastatic disease. No distant metas-
tases were evident after full staging investigations,
hence her TNM stage was IIIA [5]. In accordance with
local policy she was to be treated with three cycles
of adjuvant 5-fluorouracil (500 mg/m
2), epirubicin
(100 mg/m
2) and cyclophosphamide (500 mg/m
2)
(FEC) followed by three cycles of docetaxel (100 mg/
m
2) chemotherapy. She completed three cycles of FEC
without toxicity and was commenced on docetaxel 21
days later as per protocol. Two days after receiving
docetaxel she developed significant pain in her hands
and feet. This was followed eight days later with
marked erythema and swelling of both her hands,
which interfered with her functional activities. The
swelling subsided and marked skin desquamation
occurred over the subsequent week (Figures 1 and 2).
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by the National Cancer Institute grading system [6].
In agreement with the patient, the docetaxel che-
motherapy was discontinued and regular emollients were
prescribed. The patient was restarted on FEC chemother-
apy and received a further three cycles without toxicity.
One month after the docetaxel, her hands had signifi-
cantly improved, with only mild erythema persisting.
Discussion
PPE is a relatively common side effect of many types of
chemotherapy, namely 5-fluorouracil, capecitabine and
liposomal doxorubicin [7]. It has been reported in asso-
ciation with docetaxel in a number of case reports, initi-
ally by Zimmerman et al. in 1994 [8], but remains rare.
PPE initially presents with erythema and dysesthesia in
the palms and soles. This may progress to pain with
dryness, desquamation and ulceration. Although a num-
ber of classification systems exist, many UK based
cancer centers grade PPE as per the National Cancer
Institute. This defines grade 1 toxicity as skin changes
or dermatitis without pain, grade 2 as skin changes with
pain not interfering with function, and grade 3 toxicity
as skin changes with pain interfering with function [6].
The etiology of PPE, and why it occurs more fre-
quently with some chemotherapeutic drugs, remains
unclear and as such treatment remains symptomatic.
Currently, the most effective management is treatment
interruption and dose reduction [9]. Some success has
been achieved with the use of emollients and a number
of small studies and anecdotal reports have shown oral
pyridoxine to be useful both as a preventative and thera-
peutic measure [7].
Conclusion
PPE is a recognized toxicity occurring most commonly
with 5-fluorouracil, capecitabine and liposomal doxoru-
bicin chemotherapy. Docetaxel is frequently used in
combination with 5-fluorouracil and capecitabine for the
management of various malignant conditions including
breast, head and neck and gastric cancer [3]. When PPE
occurs as a result of the use of these combination regi-
mens, although not as commonly implicated, docetaxel
should be considered as a potential cause to avoid
mismanagement.
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Figure 1 Erythema with desquamation of the hand following
docetaxel.
Figure 2 Palmar erythema with desquamation following
docetaxel.
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